Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved Tivdak for the treatment of advanced or recurrent ...

COPENHAGEN, Denmark, March 27, 2025--Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of ...

In these regions, Pfizer partners with Genmab and Zai Lab, respectively, on commercialization. Price Action: GMAB stock is up 3.06% at $20.22 at the last check Thursday.

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, ...

The share buy-back program will start on March 26, 2025, and is expected to end no later than July 10, 2025 (unless Genmab terminates or suspends the program).